Index
All Topics
Everything Inside MedSpa covers, in one map — every section, reference tracker, recurring feature, and article. Find exactly what you need.
Sections
- Regulatory 26
- Business & M&A 97
- Devices & Tech 91
- Injectables 118
- Market 37
- Compliance 31
- Search Demand 2
- Marketing 10
- Growth & Revenue 16
- Operations 27
- Trends & Forecast 12
- Starting a Med Spa 8
Reference Guides & Trackers
- Industry Regulation, State by State
- M&A & Consolidator Tracker
- Good-Faith Exam Requirements by State (incl. Telehealth)
- Medspa Marketing Channel Benchmarks & CAC
- Medspa Industry by the Numbers: Market Size & Benchmarks
- Injectable Pricing & Rebate Tracker: Botox, Dysport, Jeuveau, Daxxify, Xeomin
- Filler Pricing & Margin Guide: Juvéderm, Restylane, RHA, Radiesse
- Medspa Treatment Pricing Benchmarks (National & Regional)
- Aesthetic Device Cost & ROI Guide
- Loyalty Program Comparison: Allē vs Aspire vs Evolus Rewards
- Medical Spa Scope-of-Practice & Supervision Rules by State
- Medspa Ownership & MSO Structure Rules by State
- Medical Director Requirements for Medspas by State
- Medspa Advertising & Claims Compliance Guide (FTC)
- GLP-1 in Aesthetics: Compounding, Sourcing & Legal Status
- Trending Aesthetic Treatments: What Patients Are Asking For
- Aesthetic Device Clearance Tracker: FDA-Cleared Energy Devices
- Neurotoxin Comparison: Botox vs Dysport vs Jeuveau vs Daxxify vs Xeomin
- Dermal Filler Comparison Guide by Type, Area & Longevity
- Energy Device Buyer's Guide: RF vs Laser vs Ultrasound vs RF-Microneedling
- Aesthetic Recall & Safety Alert Watch
- Medspa Software Comparison: Boulevard vs Aesthetic Record vs PatientNow vs Symplast
- Medspa Staffing & Salary Guide: RN Injector, NP, Aesthetician
- Medspa Startup Cost Breakdown: What It Actually Costs to Open
- Medical Spa Insurance Guide: Malpractice & Liability
- Medspa Membership & Package Pricing Models
- What Is Your Medspa Worth? Valuation & EBITDA Multiples
- Medspa M&A & Consolidator Tracker: Who's Buying
Recurring Features
- The Monday Brief — Week of Aug 02, 2026
- The Monday Brief — Week of Jul 26, 2026
- Year in Aesthetics — 2026
- Quarterly Pricing Pulse — Q3 2026
- Quarterly Device Clearance Digest — Q3 2026
- Monthly Regulatory Roundup — July 2026
- The Monday Brief — Week of Jul 19, 2026
- The Monday Brief — Week of Jul 12, 2026
- The Monday Brief: Week of Jul 05, 2026
- Quarterly Pricing Pulse — Q2 2026
- Quarterly Device Clearance Digest — Q2 2026
- Monthly Regulatory Roundup — June 2026
- The Monday Brief — Week of Jun 28, 2026
Regulatory
- AbbVie Launches Phase 2 Forehead Lines Study
- Revance Wins FDA Nod for Under-Eye Injectables
- CKD Bio Pursues China Botox Approval—2027 Launch Targeted
- AEON Releases Expanded Data on ABP-450 Botox Biosimilar
- Numeco Wins Panama Approval for Newlux Botulinum Toxin
- BOTOX Masseter Indication Moves Closer to FDA OK
- Botox Masseter Indication Moves Closer to FDA OK
- FDA Accepts BOTOX Cosmetic sBLA for Masseter Prominence
- FDA Accepts BOTOX Masseter sBLA—Jawline Approval Path Clear
- AbbVie Wins FDA Review for BOTOX Jawline Indication
- FDA Accepts sBLA for Botox in Masseter Prominence
- AbbVie Wins FDA Review for BOTOX Jawline Indication
- Indiana Tightens Medical Spa Regulations Under Public Law 136
- SKINVIVE by JUVÉDERM Gains FDA Approval for Neck Lines—New Indication Expands Filler Market
- AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs
- AbbVie Wins EU Approval for Boey, Its Rapid-Onset Botulinum Toxin
- AbbVie Wins EU Approval for Boey, Its Short-Acting Botulinum Toxin
- Medicare Begins Price Negotiation on Botox and 14 Other Drugs — Regulatory Headwind for Toxin Economics
- Medicare Begins Price Negotiation for Botox and 14 Other Drugs — Reimbursement Pressure Ahead
- Medicare Adds Botox to Price-Negotiation List — What Payers Negotiating Toxin Costs Means for Your Reimbursement
- Galderma Provides Update on Relabotulinum BLA — Third Toxin Competitor Advances Toward FDA Approval
- Galderma Updates Relabotulinum BLA Status With FDA — Third Neuromodulator Nears U.S. Approval
- Galderma Provides Update on RelabotulinumtoxinA BLA Review — Third Botulinum Toxin Competitor Advances
- Galderma's Relfydess Botox Rival Hits FDA Roadblock — What Practices Need to Know
- Galderma Gets Complete Response Letter on RelabotulinumtoxinA — What Went Wrong
- Galderma Receives Complete Response Letter for Relfydess — Botox Rival Faces Regulatory Hurdle
Business & M&A
- Allergan Aesthetics Overhauls Loyalty Program
- Evolus Expands Estyme to Canada, Australia, New Zealand
- Evolus Q2 Revenue Beats Forecast, Raises 2026 Outlook
- AbbVie Files Material Event on Allergan Aesthetics
- Evolus Posts Third Straight Profitable Quarter
- Allergan Refreshes Partner Privileges Loyalty
- Allergan Adds Quarterly Botox Rebate for Growth
- Rejuran Maker PharmaResearch Acquires Cosmetic Group
- Allergan Aesthetics Refreshes APP Loyalty Program
- Evolus Posts Break-Even Q2—Path to Sustained Profit Clear
- Beauty Health Q2 Earnings: Device Demand Steady
- Establishment Labs Raises 2026 Revenue Guidance
- Evolus Tops Q2 Revenue Forecast, Raises 2026 Outlook
- Allergan Refreshes Partner Privileges Loyalty Program
- Indonesia Opens First Botulinum Toxin Plant
- Galderma Raises 2026 Guidance After Robust H1
- Evolus Posts Third Straight Profitable Quarter
- Evolus Q2 Revenue Surges 21%, Adjusted EBITDA Swings Positive
- Perceptive Advisors Takes New Stake in Evolus
- Evolus Q2 Revenue Hits $84.1M, Raises 2026 Guidance
- Hugel Posts Record H1 Earnings on Toxin Growth
- AbbVie Files Material Event—Allē Rebate Terms Shifting
- Evolus Files Material Event—Jeuveau Pricing Escalates
- Evolus Posts Third Straight Profitable Quarter, Raises Outlook
- Evolus Files Material Event—Jeuveau Pricing Shift Ahead
- Galderma Raises 2026 Guidance After $3.1B H1 Sales
- Steel Partners Escalates InMode Pressure Over Governance
- Berenberg Backs Galderma's Integrated Model After H1 Beat
- RBC Lifts Galderma Outlook Following H1 Beat
- AbbVie Files Material Event—Botox/Juvéderm Pricing Shift Ahead
- Hugel Aesthetics Launches Direct Sales Force for Letybo, Expands US Footprint
- Galderma Posts $3.1B H1 Sales, Raises 2026 Outlook
- Hugel Aesthetics Builds U.S. Direct Sales Force for Letybo and K-TOX Campaign
- Hugel Launches Letybo in India, Expanding Asia-Pacific Footprint
- Hugel Aesthetics Builds U.S. Footprint with Direct Sales Force for Letybo and K-TOX Campaign
- Hugel Aesthetics Builds Direct Sales Force for Letybo and K-TOX in U.S. Market
- Galderma Posts Record H1 2026 Sales of $3.1B, Raises Full-Year Guidance
- Steel Partners Offers $16.75 Per Share for InMode—Device Consolidation Accelerates
- Hugel Expands US Footprint With Direct Sales Force for Letybo and New K-TOX Campaign
- Steel Partners Offers to Acquire InMode at $16.75 Per Share; Board Evaluates Rival Bids
- InMode Reports Q2 Revenue $95.2–$95.4M — Steady Growth Amid Acquisition Uncertainty
- Galderma Launches Alastin in Japan, Asia-Pacific Markets
- Steel Partners Bids $16.75 Per Share for InMode — What a Takeover Means for Device Buyers
- InMode Guides Q2 2026 Revenue to $95.2M–$95.4M, Reiterates $365M–$375M Full-Year Target
- Court Bid Filed to Pause InMode Takeover Review — Shareholder Litigation Clouds Steel Partners Offer
- Steel Partners Bids $16.75/Share for InMode — What a Takeout Means for Device Economics
- L'Oréal Raises Galderma Stake to 20%, Deepening Strategic Investment
- InMode Guides Q2 Revenue to $95.2M–$95.4M, Reiterates $365M–$375M FY 2026 Target
- Steel Partners Bids $16.75/Share for InMode — Challenging CEO Buyout
- Steel Partners Bids $16.75/Share for InMode — What a Hostile Takeover Means for Device Buyers
- L'Oréal Raises Galderma Stake to 20% — What Luxury-Goods Capital Means for Aesthetic Pricing
- Sisram Medical Restructures DAXXIFY China Deal With Fosun — Supply Chain Shift Signals Market Consolidation
- L'Oréal Raises Galderma Stake to 20% — Strategic Beauty-Pharma Convergence Play
- Sisram Medical Restructures DAXXIFY China Deal With Fosun — Botulinum Toxin Strategy Shifts
- Steel Partners Offers $16.75/Share for InMode — Rival Bid Challenges CEO Buyout
- L'Oréal Boosts Galderma Stake to 20% — Strategic Consolidation in Aesthetics
- Sisram Medical Restructures DAXXIFY China Deal With Fosun Unit — Supply Chain Complexity Deepens
- Steel Partners Bids $16.75/Share for InMode — What a Contested Takeover Means for Device Buyers
- AbbVie Allergan Aesthetics Files Material Event — Botox and Juvéderm Pricing or Loyalty Changes Likely
- Evolus Files Material Event on Jeuveau Loyalty Program — Pricing and Rebate Moves Signal Market Pressure
- Steel Partners Bids $16.75 Per Share for InMode — Unsolicited Offer Challenges CEO Buyout
- InMode Receives Unsolicited Takeover Offer — Consolidation Pressure Mounts in Device Market
- AbbVie Files Material 8-K on Allergan Aesthetics — Pricing or Rebate Shift Likely Ahead
- L'Oréal Boosts Galderma Stake to 20% — Strategic Bet on Aesthetics and Skincare Convergence
- InMode Receives Unsolicited Takeover Offer — Consolidation Pressure Mounts in Energy-Device Space
- AbbVie Files Material Event on Allergan Aesthetics — Pricing or Rebate Move Likely Incoming
- InMode Confirms Receipt of Unsolicited Takeover Proposal — Strategic Interest Signals Market Consolidation
- InMode Receives Unsolicited Buyout Proposal at $16.20 per Share — M&A Signals Consolidation Pressure
- Evolus Files Material Events — Jeuveau Pricing and Evolus Rewards Program Under Strategic Review
- AbbVie Files Multiple Material Events — Botox/Juvéderm Pricing and Rebate Moves Signal Margin Pressure
- L'Oréal Increases Stake in Galderma to 20% — Consolidation Pressure Mounts in Aesthetics
- AbbVie Allergan Aesthetics Files Multiple Material Events — Botox/Juvéderm Pricing or Allē Loyalty Shifts Imminent
- L'Oréal Boosts Galderma Stake to 20% — Strategic Consolidation in Premium Filler Market
- Evolus Files Material Event — Jeuveau Pricing or Loyalty Program Shift Likely
- AbbVie Files Multiple Material Events — Botox/Juvéderm Pricing or Rebate Adjustments Likely
- Evolus Files Material Event: Jeuveau Loyalty Program Signals Aggressive Medspa Push
- AbbVie Files Multiple Material Events — Botox/Juvéderm Pricing or Rebate Moves Imminent
- Allergan Aesthetics Files Multiple Material Events: Pricing and Rebate Moves Signal Margin Pressure
- Evolus Files Multiple Material Events — Jeuveau Pricing Strategy Intensifies
- AbbVie Files Multiple Material Events — Allergan Aesthetics Pricing and Rebate Moves Signal Margin Pressure Across Injectable Market
- Evolus Files Multiple Material Events — Jeuveau Pricing and Loyalty Program Moves Target Medspa Market Share
- AbbVie's Allergan Aesthetics Files Multiple Material Events — Pricing and Rebate Moves Ahead
- Evolus Files Multiple Material Events — Jeuveau Competitive Moves Underway
- AbbVie Files Multiple Material Events — Allergan Aesthetics Pricing or Rebate Moves Likely Ahead
- Evolus Files Multiple Material Events — Jeuveau Competitive Pricing Strategy in Motion
- Medspa Franchise vs Independent Practice: Cost, Control, and Unit Economics
- Should Your Medspa Have a Membership Program? Models, Metrics, and Revenue Impact
- How to Market a Medspa: High-Converting Channels and Real Unit Economics
- How Much Revenue Can One MedSpa Treatment Room Generate?
- How Much Does It Cost to Open a Medspa? Real Buildout, Device, and Staffing Numbers
- Boulevard vs Aesthetic Record vs PatientNow: Which Medspa Software Fits Your Practice
- What It Takes to Open a Medical Spa: Licensing, Medical Director, Ownership, and Capital Requirements
- How to Price Lip Filler at Your MedSpa: Cost Inputs, Market Rates, and Packaging Strategy
- Medspa Profit Margins: What's Normal by Service Line
- Botox Cost Per Unit and Profit Margin: The Real Economics for Medspa Owners
- InMode Receives Unsolicited $16.20-Per-Share Acquisition Proposal — Device Consolidation Accelerates
- Med Spa Valuation and Exit Basics: What Makes a Practice Worth Buying
Devices & Tech
- Sofwave Hits One Million Treatments Milestone
- Ultherapy PRIME Real-Time Imaging Reshapes Midface Lifting
- XERF Technology Enters Australian Market for Skin Tightening
- Sisram Medical H1 2026: APAC Growth Offsets Margin Pressure
- Sofwave Hits One Million Treatments Globally
- Ultherapy PRIME Clears FDA for Knee Skin
- FDA Clears Ultherapy PRIME for Knee Skin Laxity
- Apyx: GLP-1 Boom Is Fueling Renuvion Demand
- Merz Ultherapy PRIME Clears FDA for Knee Skin Laxity
- Alma Launches TitaniumLift™ Multi-Depth RF Protocol
- InMode Q2 Revenue Beats at $95.6M on Device Demand
- Ultherapy PRIME Clears FDA for Knee Skin Laxity
- Apyx Sees GLP-1 Boom Fueling Body Contouring Demand
- InMode Q2 Beats EPS Forecast, Revenue Tops Estimates
- InMode Q2 Revenue Beats Estimates at $95.6M
- Sofwave Q2 Revenue Accelerates on Ultrasonic Demand
- InMode Q2 Revenue Beats on Steady U.S. Device Demand
- InMode Q2 Beats on Steady U.S. Device Demand
- Sofwave Q2 Revenue Accelerates on Ultrasonic Demand
- Sofwave Q2 Revenue Jumps 43% YoY to $30M
- InMode Q2 Flat Revenue, Margins Compress
- RF Microneedling Adverse Events Draw Clinical Review
- Indonesia Opens Botulinum Toxin Plant—2028 Production
- SkinStylus Gets FDA Nod for Periorbital Wrinkles
- Alma Lasers Launches Harmony Platform in India—Multi-Modality Push
- Aesthetic Lasers Market Projected to Hit $11.1B by 2036
- Alma Lasers Launches Harmony Platform in India, Signals Multi-Modality Strategy
- Galderma Rolls Out Alastin Regenerative Skincare Across JPAC Region
- Cynosure Launches XERF Monopolar RF Platform in Europe — Next-Gen Skin Tightening Enters Market
- Cynosure Launches XERF Monopolar RF Platform in Europe — Next-Gen Skin Tightening Competes with Thermage
- Cynosure Lutronic Launches XERF Monopolar RF Platform in Europe
- Cynosure Lutronic Launches Next-Generation Monopolar RF in Europe — Non-Invasive Skin Tightening Demand Accelerates
- Cynosure Lutronic's XERF Accelerates Adoption as Leading Monopolar RF Platform — Competitive Pressure on InMode
- Hugel's Botulinum Toxin Manufacturing Scales to 25,000 Vials From Thumb-Sized Tube — Supply Dynamics Shift
- Hugel's Toxin Manufacturing Scales to 25,000 Vials From a Thumb-Sized Tube — Supply Chain Efficiency
- SkinStylus Receives FDA Clearance for Periorbital Wrinkles Across All Skin Types
- Cynosure Lutronic's XERF Gains Traction as Monopolar RF Leader — Market Share Shift in Body Contouring
- Fotona Reports Surge in Younger Patient Bookings for 'Collagen Banking' — Preventive Laser Trend Gains Traction
- Cynosure Lutronic's XERF Monopolar RF Platform Gains Rapid Adoption Across North America
- Fractional RF Microneedle Market Valued at $2.3B — Device Consolidation Accelerates
- Fotona4D Reports Surge in Younger Patient Bookings — 'Collagen Banking' Trend Reshapes Device Mix
- Fotona4D Reports Surge in Younger Patient Bookings — 'Collagen Banking' Trend Reshapes Device Mix
- Sisram Medical Launches China Manufacturing for Alma Rejuve — Localized Production Begins
- Sisram Medical Launches China Manufacturing for Alma Rejuve — Supply Chain Shift Underway
- Queen City Dermatology Becomes First Cincinnati Practice to Offer XERF Radiofrequency
- Cynosure's XERF Radiofrequency Now 3x Faster — Adoption Accelerates Across Clinics
- XERF Radiofrequency Adoption Accelerates — Cynosure Lutronic's Speed Advantage Reshapes Device Economics
- Cynosure Lutronic's XERF Radiofrequency System Sees Accelerating Adoption — Now 3x Faster Processing Speed
- Cynosure Lutronic's XERF Radiofrequency Now 3x Faster — Device Economics Shift
- XERF Radiofrequency Adoption Accelerates — Cynosure Lutronic Reports 3x Speed Improvement
- Aesthetic Laser Costs: Price Ranges by Modality and Break-Even Economics
- CoolSculpting vs Emsculpt vs truSculpt vs SculpSure: Body-Contouring ROI for Medspa Owners
- HydraFacial vs. Regular Facial: Clinical Mechanism, Economics, and Menu Positioning for Medspa Owners
- Microneedling vs RF Microneedling: Clinical Depth, Energy Delivery, Results, and Device ROI for Practice Owners
- Exosomes in Aesthetics: What the Science Shows and Why the FDA Hasn't Approved Them
- Ellacor: How Candela's Micro-Coring Technology Works and What FDA Approval Means for Your Practice
- Emsculpt NEO: HIFEM + RF Body Contouring for Medspa Owners
- Emface: How BTL's Needle-Free HIFES + RF Lift Works and What It Means for Your Practice
- Morpheus8 Machine Cost: Acquisition, Consumables, and Break-Even Patient Volume
- What Is Sofwave? How Ultrasound Microthermal Therapy Works for Skin Tightening
- PDO Thread Lifts: How They Work, Results, Longevity, and Risk Profile
- PRP vs PRF in Aesthetics: Preparation, Clinical Uses, and Evidence
- RF Microneedling: How It Works, Clinical Indications, and Leading Devices
- What Is Morpheus8? RF Microneedling Technology, Clinical Applications, and Practice Economics
- Ultherapy vs Sofwave: Comparing Ultrasound and Radiofrequency Skin Tightening
- CoolSculpting vs Emsculpt: Mechanisms, Results, and Practice Economics
- Morpheus8 vs. Vivace: RF Microneedling Depth, Results, and Practice ROI Compared
- The Used / Gray-Market Device Question: Service Lockouts, Liability, and When It's a Trap
- The Body Contouring Buy Decision: Cryolipolysis vs RF vs HIFU vs Muscle-Stim on Demand and Repeat Rate
- Warranty and Service-Contract Negotiation: The Clauses That Cost You Later
- Device ROI Models That Actually Hold Up: Treating $/Pulse, Consumables, and Downtime as Real Costs
- Reading a Device Clinical Claim: '510(k) Cleared For' vs What the Rep Is Implying It Does
- Lease vs Finance vs Buy on a $120K Platform: The Tax and Cash-Flow Math Reps Won't Show You
- What Is a 'Vampire Facial'? The PRP Treatment Behind the Name, for Owners
- Chemical Peel vs Microdermabrasion: Matching Exfoliation Intensity to the Patient
- IPL vs BBL: Understanding the Light-Based Options Patients Ask About
- Microneedling vs Laser Resurfacing: Two Routes to Skin Renewal, Different Intensity and Cost
- What Is Microchanneling? Understanding a Microneedling-Adjacent Treatment
- The Consumables Trap: Why 'Cheap' Energy Devices With Per-Tip Costs Beat You on Margin
- Muscle vs Fat Body Contouring: Comparing Energy-Based Approaches for Owners
- HydraFacial vs Dermaplaning: Two Popular 'Glow' Treatments Compared
- How Much Does CoolSculpting Cost — and Does the Device Math Work for Your Practice?
- CoolSculpting vs Liposuction: Non-Invasive Device vs Surgical Fat Removal
- How Much Does Microneedling Cost — and How Owners Should Price the Series
- How Many Microneedling Sessions — Framing the Series for Results and Revenue
- Laser vs IPL for Pigmentation: Choosing the Right Light for the Concern
- Chemical Peel vs Laser Resurfacing: Matching the Treatment to the Patient and the Downtime
- Microneedling vs Chemical Peel: Two Routes to Better Skin Texture
- PRP vs Microneedling: How They Differ and Why They're Often Done Together
- Laser Hair Removal vs Electrolysis: Two Approaches to Hair Reduction
- PRP for Hair Restoration: An Owner's Overview of a Growing Service Line
Injectables
- AEON Releases Expanded ABP-450 Botox Biosimilar Data
- RHA Redensity Eye Wins FDA Nod for Under-Eye Hollows
- Juvéderm Day Returns With Significant Filler Pricing
- Daxxify Duration Claims vs. Reality
- Galderma Wins EU Nod for Restylane Shaype
- MOLD Manila Rolls Out Radiesse for Facial Rejuvenation
- AbbVie's Botox Sales Surge—What's Driving the Revival
- Hugel Posts Record H1 on Toxin Surge—Overseas Growth Accelerates
- Galderma Wins EU Nod for Restylane Shaype
- Hugel Debuts Thechaum Signature with Reduced Crosslinker
- GLP-1 Boom Exposed Filler Limitations—Here's Why
- Galderma Chief: Start GLP-1 Patients on Skin Care First
- Evolus' Injectable Platform Is Becoming Its Real Moat
- AbbVie Launches Boey, Rapid-Onset Toxin, in Europe
- JUVÉDERM Day Returns August 19—Promo Details
- SKINVIVE Neck-Line Indication Expands Filler Market
- Galderma Launches Sculptra in India—Regenerative Expansion
- AbbVie Q2 2026: Aesthetics Growth Outpaces Pharma
- Evolus Q2 2023: Revenue Breakdown Signals Jeuveau Stabilization
- Daewoong's Nabota Reaches 1 Trillion Won in Cumulative Sales, Signals Korean Toxin Momentum
- AbbVie Launches Boey, Rapid-Onset Botulinum Toxin, With EU Approval
- Xeomin Enters Neurotoxin Resistance Conversation as Clinical Data Accumulates
- Hugel Builds US Direct Sales Force for Letybo, Launches K-TOX Campaign
- Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neuromodulator
- AbbVie's Boey Wins EU Approval for Frown Lines — First Rapid-Onset Botox Alternative
- Daewoong Pharma's Nabota Surpasses 1 Trillion Won in Sales — South Korean Toxin Accelerates Global Expansion
- Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neuromodulator
- Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neurotoxin Reshapes Toxin Economics
- Evolus Expands Jeuveau Rewards Program — Aggressive Pricing War Targets Medspa Market Share
- Evolus Aggressively Markets Jeuveau Through Rewards Program — Neuromodulator Price Wars Intensify
- Daewoong Pharma's Nabota Exceeds 1 Trillion Won in Sales, Accelerates Global Push
- Evolus Ramps Jeuveau Marketing to Medspas via Evolus Rewards Program
- Evolus Aggressively Markets Jeuveau to Medspas via Rewards Program — Price War Signals Intensify
- AbbVie Allergan Files Material Event — Botox/Juvéderm Pricing or Rebate Shift Likely Imminent
- Evolus Secures Exclusive U.S. License for Profhilo — 15-Year Term, No Upfront Fee
- Evolus Secures Exclusive U.S. Profhilo License From IBSA — Skin Quality Injectable Now in Play
- Evolus Secures Exclusive U.S. Profhilo License From IBSA — A Skin-Quality Play to Challenge Juvéderm
- Evolus Secures Exclusive U.S. Rights to Profhilo From IBSA — 15-Year Term, No Upfront Fee
- Allergan Wins FDA Nod for SKINVIVE by JUVÉDERM for Neck — New Indication, Familiar Economics
- Allergan Aesthetics Wins FDA Approval for SKINVIVE by JUVÉDERM for Neck — First Indication Expansion
- AbbVie Wins FDA Approval for SKINVIVE by JUVÉDERM for Neck — First Filler Indication in Category
- FDA Approves Restylane Contour for Temple Hollowing — Galderma Expands Filler Indication Portfolio
- FDA Approves Skinvive by Juvéderm for Neck Appearance — AbbVie Expands Filler Portfolio Beyond Face
- Galderma Wins FDA Approval for Restylane Contour — Temple Indication Expands Structural Filler Segment
- Allergan Aesthetics Wins FDA Approval for Skinvive by Juvéderm — Neck Indication Expands Filler Portfolio
- AbbVie Wins FDA Approval for Skinvive by Juvéderm — Neck Indication Expands Filler Portfolio
- Galderma Wins FDA Approval for Restylane Contour — Temple Hollowing Indication Expands Filler Anatomy
- Galderma Wins FDA Clearance for Restylane Contour — Temple Hollowing Now Indicated
- Restylane Contour Approved for Temple Hollowing — Galderma Fills a Clinical Gap
- RHA Dynamic Volume Cleared for Midface Augmentation — Revance Expands Dynamic Filler Footprint
- FDA Approves Skinvive by Juvéderm for Neck Lines — New Indication Expands Allergan's Dermal Filler Portfolio
- Galderma's Restylane Contour Cleared for Temple Hollowing — New Indication, Familiar Filler
- Skinvive by Juvéderm Wins FDA Approval for Neck — What's in Your Filler Mix Now
- Supply-Disruption Early Warning: Reading 483s and Recalls to Stock Ahead of a Shortage
- FDA Approves Skinvive by Juvéderm for Neck Appearance — What the Indication Means for Your Juvéderm Mix
- Galderma Wins FDA Clearance for Restylane Contour in Temple Hollowing — Narrower Indication, Broader Competitive Pressure
- FDA Clears RHA Dynamic Volume for Midface Augmentation — Revance's Dynamic Filler Gains Broader Indication
- How Hyaluronidase Dissolves Filler: Mechanism, Vascular Occlusion Protocol, and Practice Liability
- Botox Units Per Area: Standard Dosing and Practice Economics
- RHA vs Juvéderm: Resilient HA and Vycross Technology Compared for Aesthetic Practice
- Daxxify vs Jeuveau: Duration, Cost, and Clinical Positioning
- Botox vs Xeomin: Which Neuromodulator to Stock and Offer Your Patients
- What Is a Liquid Facelift? Filler and Toxin Combination Strategy for Medspa Owners
- What Is a Skin Booster? Category, Players, FDA Status, and Menu Strategy
- Skinvive by Juvéderm: The Microdroplet HA Skin Booster for Cheek Hydration
- What Is Rejuran? The Polynucleotide Skin Booster Reshaping the Aesthetic Market
- Letybo vs. Botox: Key Differences in Units, Onset, and Clinical Profile for Medspa Owners
- Is Relfydess FDA Approved? Status, Mechanism, and How It Compares to Dysport
- Is Evolysse FDA Approved? Evolus's HA Filler Line Explained
- Sculptra vs Radiesse: Mechanism, Timeline, and Clinical Use Cases for Medspa Owners
- Juvéderm vs Restylane: HA Filler Families Compared by Crosslinking, Indication, and Longevity
- Daxxify vs Botox: Duration, Cost, and When to Use Each
- Botox vs Jeuveau: Which Neuromodulator to Stock and Offer
- Botox vs Dysport: Clinical Differences, Dosing, and Economics for Injectors
- Is Kybella FDA Approved? Current Status and What Medspa Owners Need to Know
- Is Sculptra FDA Approved? Status, Indications, and Clinical Use
- Are RHA Fillers FDA Approved? Current Status and Clinical Use
- Is Xeomin FDA Approved? Status, Indications, and Clinical Profile
- Is Skinvive by Juvéderm FDA Approved? Status, Indications, and Microdroplet Technology
- Is Letybo FDA Approved? Status, Mechanism, and Clinical Position
- Is Jeuveau FDA Approved? Current Status and Clinical Indications
- Is Daxxify FDA Approved? Status, Indications, and How It Compares to Botox
- Allergan Aesthetics Wins Health Canada Approval for Boey — Rapid-Onset Neuromodulator Clears Regulatory Hurdle
- Allergan Aesthetics Wins FDA Approval for Skinvive by Juvéderm — Neck Wrinkles Now Cleared
- RHA Dynamic Volume Wins FDA Clearance for Midface Augmentation — New Rheology Profile Enters Market
- Biostimulator Supremacy: Why Sculptra-Class Products Are Eating Filler's Lunch
- Manufacturer Contract Season: How to Negotiate Volume Tiers Before You Re-Sign
- Building a Tox-and-Filler Loyalty Stack: Layering Allē, Aspire, and Evolus Rewards Without Cannibalizing Margin
- Anticipating the Next Injectable Price Increase: The Signals That Precede a List-Price Hike
- Hyaluronidase Protocols: Stocking, Dosing, and the Vascular-Occlusion Emergency Kit Every Room Needs
- Filler Rheology for Owners: G-Prime, Cohesivity, and Why It Dictates Which Product for Which Plane
- Switching Your Tox: The Operational Playbook for Inventory, Retraining, Patient Comms, and the Rebate Reset
- Cannula vs Needle Economics and Liability: When the Safer Technique Is Also the Better Margin
- Managing Tox Resistance and Neutralizing Antibodies: Counseling the Patient and Switching Formulations
- The Real Cost-Per-Unit Breakdown: Botox vs Dysport vs Jeuveau vs Daxxify vs Letybo (Loaded, Not List)
- Dysport-to-Botox Conversion Ratios in Practice: Pricing and Dosing When You Run Both
- Kybella vs CoolSculpting for the Double Chin: Injectable vs Device for Submental Fat
- Reconstitution & Dilution Economics: How Your Saline Volume Quietly Changes Your Cost-Per-Unit
- How Long Does Botox Take to Work — and Why the Answer Is a Retention Tool
- Overfill Math: Getting 22–25 Units Out of a '20-Unit' Vial Without Compromising Results
- Jawline Definition: The Treatment Options and the Consult That Sells the Plan
- PRF vs Filler for the Under-Eye: Two Approaches to a Delicate Area
- Diffusion Profiles That Matter Chairside: Why Field-of-Effect Changes Your Injection Map by Product
- Restylane vs RHA: How Owners Should Think About Two HA Filler Families
- Radiesse vs Hyaluronic Acid Filler: Biostimulator-Type vs HA Volume
- Treating Under-Eye Concerns: Matching the Approach to the Cause (an Owner's Overview)
- Dysport vs Daxxify: Diffusion and Duration as the Two Axes That Matter
- 'Baby Botox' vs Traditional Dosing: Subtlety as a Treatment Philosophy
- How Long Does Dysport Last — and Using Onset and Duration to Set Expectations
- Thread Lift vs Filler: Lift vs Volume, and Setting the Right Patient Expectation
- Filler vs Fat Transfer: Injectable Volume vs a Surgical Approach
- How Long Does Lip Filler Last — and How Owners Should Use That for Rebooking Cadence
- Lip Flip vs Lip Filler: Two Different Treatments Patients Constantly Confuse
- How Much Does Sculptra Cost — and How Owners Should Price the Biostimulator Series
- Semaglutide vs Tirzepatide for Medspas: What Owners Need to Know About Offering Each
- How Much Does Lip Filler Cost — and How Owners Should Frame Lip Pricing
- Dysport vs Jeuveau: Two Neurotoxin Alternatives in Different Lanes
- Botox vs Fillers: When Each Is the Right Tool (and Why Patients Confuse Them)
Market
- GLP-1 Pill Era Is Forcing Beauty Market Shift
- Arm Fat Now Top Body Sculpting Concern in Singapore
- Facial Rejuvenation Market Forecast to Hit $5.66B by 2030
- Medytox Q2 Sales Up 11%, Operating Profit Down 25%
- Hugel Posts Record H1 Revenue on Overseas Toxin Surge
- South Korea's Big Three Post ₩225.9B Q2 Revenue
- Daewoong's NABOTA Enters Seventh Middle East Market
- Daewoong's Nabota Completes 7-Market GCC Sweep
- GLP-1 Weight Loss Boom Lifts Galderma Aesthetics Sales 25%
- Daewoong's Nabota Enters Kuwait—Completes 7-Market GCC Sweep
- Daewoong's Nabota Enters Kuwait—7th Middle East Market
- Galderma Capitalizes on GLP-1 Weight-Loss Trend—What Practices Need to Know
- Daewoong's Nabota Hits 1 Trillion Won in Cumulative Sales—Asian Toxin Market Matures
- "Ozempic Face" Facials Driving Botox Boom as GLP-1 Users Seek Preventive Aesthetics
- Galderma Capitalizes on GLP-1 Weight Loss Trend—What Practices Should Know
- Daewoong's Nabota Crosses 1 Trillion Won in Cumulative Sales—Asian Toxin Gains Scale
- "Ozempic Face" Facials Driving Botox Boom—Practices Capitalize on GLP-1 Side Effect
- Galderma Capitalizes on GLP-1 Weight Loss Trend; 'Ozempic Face' Drives Filler and Toxin Demand
- Hugel Launches Letybo in India — Expanding Asia-Pacific Footprint
- Hugel Launches Letybo in India, Targets 9% Market Share by 2026
- Galderma Raises Full-Year Guidance After Record First-Half Sales of $3.13B
- Hugel Launches Letybo in India, Targets 9% Market Share by 2026
- GLP-1 Aesthetic Care Market Projected to Reach $2B by 2030 — New Revenue Stream for Medspa Operators
- InMode Guides Q2 Revenue to $95.2M–$95.4M — Growth Resilience Amid Takeover Uncertainty
- InMode Projects Q2 Revenue $95.2M–$95.4M, Reiterates $365M–$375M FY 2026 Guidance
- GLP-1 Aesthetic Care Market Projected to Hit $2B by 2030 — New Revenue Stream or Threat?
- Daewoong's Nabota Hits 1 Trillion Won in Sales — Korean Toxin Maker Accelerates U.S. and Global Expansion
- GLP-1 Weight-Loss Boom Drives Post-Bariatric Body Contouring Surge — New Patient Pipeline for Medspas
- InMode Guides Q2 2026 Revenue to $95.2M–$95.4M; Full-Year Outlook Holds at $365M–$375M
- GLP-1 Weight-Loss Boom Drives Post-Reduction Body Contouring at Medspa Practices — New Revenue Stream Emerging
- GLP-1 Weight-Loss Boom Fuels Body-Contouring Volume — Practices Report Surge in Post-Weight-Loss Procedures
- GLP-1 Weight Loss Boom Drives Post-Loss Body Contouring Demand at Aesthetic Practices
- Fotona4D Reports Surge in Younger Patient Bookings — 'Collagen Banking' Becomes 2026 Trend
- Semaglutide Pricing at Medspas: Compounded vs. Branded and What Patients Actually Pay
- Semaglutide Face: Why Medspa Owners Should Offer Fillers to GLP-1 Patients
- Offering GLP-1 Weight Loss at a Medspa: Sourcing, Compliance, and Revenue Model
- GLP-1 Weight Loss Boom Drives 'Semaglutide Face' — Aesthetic Practices Report Surge in Volume Restoration Demand
Compliance
- Warning: Unauthorized Injectables Seized in Canada
- Evolus Rewards Program Terms Changed—Review Now
- Daewoong Tightens Nabota Distribution After Gray-Market Leak
- Alert: SkinMedica/Allergan Brand Terms Page Updated — Review Your Loyalty Program Now
- SkinMedica/Allergan Program Terms Shifted — Verify Rebate and Loyalty Thresholds Now
- Can a Medspa Prescribe Semaglutide? Scope, Regulations, and State Variation
- How to Find and Hire a Medical Director for Your Medspa
- Do You Need to Be a Doctor to Own a Medspa? Ownership Rules and MSO Structures
- Can a Nurse Practitioner Own a Medical Spa? State Rules, CPOM, and MSO Structures
- Is Compounded Semaglutide Legal for Medspas? FDA Status, Compounding Rules, and Enforcement Risk
- Medical Director Requirements for Medspas: Role, Supervision, and Liability
- Can an RN Inject Botox Without a Doctor? State Scope-of-Practice Rules and Supervision Requirements
- Good Faith Exam Requirements for Medical Spas: What Owners Need to Know
- Non-Compete and Non-Solicit for Injectors: What's Enforceable After the FTC Rule Shakeout
- Med Spa Advertising Law: The FTC and State-Board Rules on 'Results,' Testimonials, and Influencer Posts
- The Patient Intake and Contraindication Reference: Screening That Prevents the Lawsuit
- OSHA in an Aesthetic Practice: The Bloodborne-Pathogen and Hazard Citations Owners Miss
- Handling an Adverse Event: The Documentation, Reporting, and Board-Complaint Survival Guide
- Corporate Practice of Medicine, Decoded: Why Your Ownership Structure May Be Illegal in Your State
- IV Therapy's Regulatory Gray Zone: Compounding, Standing Orders, and the New Scrutiny
- HIPAA for Medspas: The Before/After Photo, Texting, and Social-Media Consent Failures That Get Fined
- Injectable Storage, Handling, and Cold-Chain Requirements: The Compliance Checklist
- Delegation and Incident-To: Who Can Legally Inject in Your State, and the Supervision Tiers
- Medical Waste and Sharps Disposal: The Compliance Basic That's Easy to Get Wrong
- The 'Tox Party' Compliance Trap: Why Group Events Trigger Good-Faith-Exam and Supervision Problems
- Medical Director on Paper vs in Practice: What 'Supervision' Actually Requires in a CPOM State
- Emergency Protocols: Being Ready for the Rare, Serious Event
- Telehealth in Aesthetics: Where Remote Evaluation Fits and Where It Doesn't
- Chart and Documentation Standards: The Records That Protect You When It Matters
- Good-Faith Exam Done Right: Building a Defensible Workflow With Telehealth and Standing Orders
- The MSO / Management-Services Model: How It's Used, Where It Breaks, and What Regulators Look For
Search Demand
Marketing
- Email and SMS That Aren't Spam: The Lifecycle Flows That Drive Repeat Visits
- Reputation Management: Turning Reviews Into Your Strongest Acquisition Channel
- Using the Meta Ad Library to See Exactly What Your Competitors Are Promoting
- Meta and Google Ads for Aesthetics: CAC Benchmarks and the Creative That Converts
- The Compliant Before/After: Posting Results Without Triggering Board or Platform Violations
- Before/After Photography: Why Consistent, Quality Images Are a Business Asset
- Optimizing Your Google Business Profile: The Single Most Important Local SEO Asset
- Med Spa SEO: Ranking for '[Treatment] Near Me' in a Saturated Local Market
- Instagram for Med Spas: Building Trust and Demand Without Burning the Channel
- The Med Spa Website That Converts: Turning Traffic Into Booked Consults
Growth & Revenue
- The Rebooking System: How Top Practices Hit 70%+ Rebooking at Checkout
- Reactivation Campaigns: Winning Back the Lapsed Patients Already in Your Database
- Building Treatment Packages That Increase AOV Without Discounting Yourself to Death
- Retail and Skincare Attach: Turning Medical-Grade Skincare Into Real Margin
- The Consultation-to-Treatment Conversion Playbook: Scripts, Pricing Reveals, and Objection Handling
- Pricing Psychology for Aesthetics: Anchoring, Per-Unit vs Per-Area, and the Premium Position
- Cross-Sell Maps by Service: What to Recommend Next After Tox, After Filler, After a Laser Series
- Bundling Injectables With Skincare: Building Higher-Value, Stickier Treatment Plans
- Building a Signature Treatment: Differentiation Through a Branded, Owned Offering
- Pricing Transparency: How Much to Show, and What It Signals
- Knowing Your Patient Segments: Why Not All Patients Are Equally Valuable
- Designing a Med Spa Referral Program That Actually Drives Referrals
- Competitive Positioning: Choosing What You Are Instead of Competing on Everything
- New-Patient Offers: Attracting First Visits Without Training a Discount Habit
- Should You Charge a Consultation Fee? The Strategy Behind the Decision
- Memberships vs Packages: Which Recurring-Revenue Model Fits Your Practice
Operations
- The Second-Location Decision: The Financial and Operational Signals You're Actually Ready
- The Pricing Power Audit: How to Raise Prices 10–15% and Keep Your Patients
- The RN-Injector Comp Arms Race: Structuring Pay to Retain Without Destroying Margin
- Patient Financing Done Right: Cherry, Wisetack, PatientFi, and the True Cost of 'Free' Financing
- No-Show and Cancellation Economics: Deposit Policies That Cut Losses Without Killing Bookings
- Inventory and Vial Shrinkage Control: Where Product (and Money) Actually Disappears
- Reading Your Own P&L Like an Aesthetic CFO: The Benchmarks That Flag a Sick Practice
- Chair and Room Utilization: The Single Metric That Predicts Whether You Should Expand
- Cost-of-Goods Targets by Service Line: What Your Injectable, Laser, and Skincare COGS Should Be
- Seasonal Demand in Aesthetics: Planning Inventory, Staffing, and Marketing Around the Calendar
- Managing Your Manufacturer Reps: Getting Value Without Being Managed by Them
- Gift Cards and Pre-Paid Strategy: Cash Now, Liability Later, and How to Handle Both
- When to Add a New Service Line: The Discipline Behind a Bigger Menu
- Staff Retention Beyond Injectors: Keeping the Team That Runs the Practice
- Handling Refund and Walkout Requests: Policy, Judgment, and Protecting the Relationship
- Cash-Flow Management for Med Spas: Why Profitable Practices Still Run Out of Money
- Online Booking: Reducing the Friction Between Interest and Appointment
- Injectable Inventory Management: Par Levels, Expiration, and Capital Efficiency
- Provider Compensation Models: Hourly vs Commission vs Hybrid and How Each Warps Behavior
- Handling the Unhappy Patient: Turning Complaints Into Retention (or at Least Avoiding Escalation)
- Treatment Room and Practice Flow: Designing Space for Efficiency and Experience
- Designing the Patient Experience: The Differentiator That Survives Price Competition
- The Front Desk Is Your Highest-Leverage Hire: What to Train and Why It Pays
- Treating the Needle-Anxious Patient: Comfort as a Conversion and Retention Tool
- Financial Benchmarks by Stage: What 'Healthy' Looks Like as a Practice Grows
- The Med Spa KPIs Worth Tracking: The Handful of Numbers That Actually Run the Business
- Aftercare That Drives Results and Retention: The Underused Touchpoint
Trends & Forecast
- The Consolidation Wave: Reading the PE Roll-Up Cycle and What It Means If You Don't Sell
- The Longevity Crossover: How Aesthetics Practices Are Becoming Wellness and Longevity Clinics
- AI in the Treatment Room: Imaging, Consult Tools, and Outcome Prediction Worth Adopting
- The Regenerative Aesthetics Wave: Exosomes, PRF, Polynucleotides, and What's Real vs Hype
- The Men's Aesthetics Inflection: Sizing the Segment and the Services That Actually Convert Men
- The Year in Medical Aesthetics: An Owner's State-of-the-Industry Recap
- Injectable Pipeline Watch: How to Read What's Heading for FDA Decisions Before It Hits Your Market
- Korean Aesthetics Coming West: Skin Boosters, 'K-Tox,' and What US Owners Should Prepare For
- Polynucleotide and 'Salmon Sperm' Boosters: The Demand Curve and the US Regulatory Catch
- What to Watch in Medical Aesthetics in 2026: The Shifts That Will Move Your Revenue
- Building a Regulatory Watch: Tracking the Scope-of-Practice and FDA Activity That Affects You
- At-Home and Hybrid Devices: Threat to Your Treatments or Funnel Into Them?
Starting a Med Spa
- Your First 90 Days Open: The Launch Checklist That Fills the Schedule
- Hiring Your First Injector: Credentialing, Comp, and the Supervision Setup
- Choosing Your Legal Structure: PC vs LLC vs MSO and the Ownership Rules by State
- The Med Spa Business Plan That Gets Funded: Pro Formas, Assumptions, and Lender Expectations
- Med Spa vs Day Spa: The Distinction That Shapes Everything From Services to Compliance
- The Medical Director Agreement: What to Pay, What to Require, and What to Put in Writing
- Evaluating Injector Training: What Separates Genuine Competency From a Weekend Certificate
- How to Open a Med Spa: The Complete Regulatory, Financial, and Operational Roadmap